Guggenheim Raises PT After Actavis (ACT) Has 1Q15 EPS Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Guggenheim Raises PT After Actavis (ACT) Has 1Q15 EPS Beat

Actavis Reports Exceptional Performance in First Quarter 2015 with 59% Increase in Net Revenue to $4.2 Billion and 23% Growth in Non-GAAP EPS to $4.30

May 11, 2015 6:30 AM EDT

DUBLIN, May 11, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today reported continued exceptional performance with net revenue increasing 59 percent to $4.23 billion for the quarter ended March 31, 2015, compared to $2.66 billion in the first quarter 2014. On a non-GAAP basis, diluted earnings per share increased 23 percent to $4.30 for the first quarter 2015, compared to $3.49 in the first quarter 2014.  Non-GAAP earnings per share excluding Allergan and financing (shares and interest expense) related to Allergan was $4.59, representing 17 percent sequential improvement. GAAP loss per share for the first quarter 2015 was $1.85, compared to GAAP income per diluted share... More

Actavis to Re-launch Generic Pulmicort RESPULES® Following Favorable Appeals Court Ruling

May 7, 2015 4:06 PM EDT

DUBLIN, May 7, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it will immediately re-launch its generic version of AstraZeneca's Pulmicort RESPULES® (budesonide inhalation suspension) 0.25 and 0.5 mg vials following a decision from the United States Court of Appeals for the Federal Circuit to uphold a lower court's ruling that United States Patent No. 7,524,834 is invalid.  The Appeals court also dissolved the injunction preventing Actavis from further distribution of its generic version of Pulmicort RESPULES® that was granted on March 12, 2015.

Logo -... More